The drugmakers plan to start a clinical trial in April testing the freeze-dried vaccine in 1,100 adults ages 18 to 55 in the U.S. The trial is scheduled to last about two months, and if successful, the freeze-dried version could be ready for use by early next year, the Journal reported.
Freeze-dried vaccines only require standard refrigeration. Existing freeze-dried vaccines include those used for shingles and rotavirus, according to the Journal.
Read the full article here.
More articles on pharmacy:
Pfizer, BioNTech to boost COVID-19 vaccine manufacturing to 2.5B doses
GSK to produce Novavax COVID-19 vaccine
Pfizer says its vaccine is 100% effective in preventing COVID-19 in adolescents
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
